Total Payments
$6,520
2024 Payments
$2,037
Companies
31
Transactions
283
Medicare Patients
3,526
Medicare Billing
$2.0M
Payment Breakdown by Category
Food & Beverage$6,401 (98.2%)
Education$118.69 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,401 | 281 | 98.2% |
| Education | $118.69 | 2 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $851.90 | 42 | $0 (2024) |
| UCB, Inc. | $824.53 | 33 | $0 (2024) |
| Janssen Biotech, Inc. | $687.49 | 30 | $0 (2024) |
| ABBVIE INC. | $638.91 | 29 | $0 (2024) |
| PFIZER INC. | $486.00 | 29 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $465.68 | 21 | $0 (2024) |
| Horizon Therapeutics plc | $420.73 | 12 | $0 (2023) |
| GlaxoSmithKline, LLC. | $307.05 | 11 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $215.04 | 9 | $0 (2024) |
| Lilly USA, LLC | $213.45 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,037 | 84 | Amgen Inc. ($417.22) |
| 2023 | $1,506 | 51 | AbbVie Inc. ($358.84) |
| 2022 | $1,036 | 52 | PFIZER INC. ($165.95) |
| 2021 | $924.02 | 46 | UCB, Inc. ($225.03) |
| 2020 | $426.23 | 23 | Amgen Inc. ($109.71) |
| 2019 | $574.20 | 26 | Horizon Therapeutics plc ($133.28) |
| 2017 | $16.96 | 1 | GlaxoSmithKline, LLC. ($16.96) |
All Payment Transactions
283 individual payment records from CMS Open Payments — Page 4 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/07/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: IMMUNOLOGY | ||||||
| 02/05/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: Inflammation | ||||||
| 01/30/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $21.47 | General |
| 01/22/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $32.13 | General |
| 01/18/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: Immunology | ||||||
| 01/17/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $5.77 | General |
| Category: Inflammation | ||||||
| 01/08/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: Inflammation | ||||||
| 01/04/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $31.00 | General |
| Category: Immunology | ||||||
| 01/04/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $31.15 | General |
| 12/12/2023 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Inflammation | ||||||
| 12/11/2023 | Amgen Inc. | Enbrel (Biological), TAVNEOS | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Inflammation | ||||||
| 12/06/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/30/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: KRYSTEXXA | ||||||
| 11/22/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $31.43 | General |
| Category: IMMUNOLOGY | ||||||
| 11/16/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.50 | General |
| Category: IMMUNOLOGY | ||||||
| 11/09/2023 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Immunology | ||||||
| 11/08/2023 | Amgen Inc. | Enbrel (Biological), TAVNEOS | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: Inflammation | ||||||
| 11/02/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $120.13 | General |
| Category: KRYSTEXXA | ||||||
| 10/31/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: KRYSTEXXA | ||||||
| 10/30/2023 | Medtronic, Inc. | VANTA ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $85.41 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 10/19/2023 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: IMMUNOLOGY | ||||||
| 09/12/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $120.82 | General |
| Category: IMMUNOLOGY | ||||||
| 08/24/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: KRYSTEXXA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 600 | 52,301 | $1.0M | $509,497 |
| 2022 | 20 | 998 | 73,934 | $1.4M | $726,998 |
| 2021 | 23 | 1,090 | 51,517 | $744,206 | $457,849 |
| 2020 | 21 | 838 | 33,700 | $549,505 | $345,606 |
Total Patients
3,526
Total Services
211,452
Medicare Billing
$2.0M
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 17 | 6,325 | $370,013 | $212,772 | 57.5% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 18 | 43,600 | $381,500 | $170,915 | 44.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 256 | 529 | $105,800 | $47,952 | 45.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 42 | 296 | $39,072 | $18,842 | 48.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 36 | 164 | $65,600 | $18,719 | 28.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 1,020 | $26,520 | $18,519 | 69.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 73 | 73 | $18,250 | $8,828 | 48.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 50 | $12,000 | $7,167 | 59.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 47 | 51 | $7,650 | $3,817 | 49.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $2,090 | $821.11 | 39.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 11 | 11 | $1,440 | $616.22 | 42.8% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 12 | 60 | $1,800 | $440.25 | 24.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 27 | 111 | $297.48 | $88.53 | 29.8% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 21 | 62,400 | $546,000 | $276,061 | 50.6% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 13 | 7,775 | $454,838 | $268,638 | 59.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 297 | 735 | $147,000 | $71,583 | 48.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 14 | 1,500 | $39,000 | $25,778 | 66.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 35 | 342 | $45,144 | $22,659 | 50.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 31 | 172 | $68,800 | $20,817 | 30.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 125 | 125 | $31,250 | $16,685 | 53.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 40 | 63 | $15,120 | $8,204 | 54.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 83 | 101 | $15,150 | $6,505 | 42.9% |
| 86235 | Measurement of antibody for assessment of autoimmune disorder, any method | Office | 2022 | 18 | 126 | $2,520 | $2,235 | 88.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 19 | 32 | $4,723 | $1,735 | 36.7% |
| 82306 | Vitamin d-3 level | Office | 2022 | 51 | 54 | $2,160 | $1,584 | 73.3% |
About Dr. Louis Robinett, M.D
Dr. Louis Robinett, M.D is a Rheumatology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2014. The National Provider Identifier (NPI) number assigned to this provider is 1780002956.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Louis Robinett, M.D has received a total of $6,520 in payments from pharmaceutical and medical device companies, with $2,037 received in 2024. These payments were reported across 283 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($6,401).
As a Medicare-enrolled provider, Robinett has provided services to 3,526 Medicare beneficiaries, totaling 211,452 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Austin, TX
- Active Since 04/03/2014
- Last Updated 04/28/2025
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1780002956
Products in Payments
- Cimzia (Drug) $787.06
- KRYSTEXXA (Biological) $491.95
- XELJANZ (Drug) $452.98
- RINVOQ (Biological) $430.11
- TREMFYA (Drug) $352.88
- Enbrel (Biological) $248.12
- COSENTYX (Drug) $246.90
- ORENCIA (Biological) $211.94
- TALTZ (Drug) $192.26
- Otezla (Drug) $178.40
- OFEV (Drug) $175.34
- REMICADE (Biological) $174.69
- BENLYSTA (Biological) $168.26
- COSENTYX (Biological) $162.27
- TAVNEOS (Drug) $161.69
- EVENITY (Biological) $161.68
- KEVZARA (Biological) $137.58
- SKYRIZI (Biological) $137.15
- SAPHNELO (Biological) $125.06
- NUCALA (Biological) $121.83
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Austin
Dr. Robert Koval, Md, MD
Rheumatology — Payments: $67,062
Rheumatology $67,062
Paul Pickrell, Md, MD
Rheumatology — Payments: $29,321
Rheumatology $29,321
Joseph Martinez, Md, MD
Rheumatology — Payments: $21,904
Rheumatology $21,904
Marco Lopez Velazquez, M.d, M.D
Rheumatology — Payments: $3,941
Rheumatology $3,941
Sonia Yousuf, Md, MD
Rheumatology — Payments: $2,974
Rheumatology $2,974
Dr. Samir Patel, M.d, M.D
Rheumatology — Payments: $1,565
Rheumatology $1,565